Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have been assigned an average recommendation of "Hold" from the nine ratings firms that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $87.00.

Several analysts have recently issued reports on the company. StockNews.com cut Hologic from a "buy" rating to a "hold" rating in a report on Friday, March 8th. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Friday, February 2nd. Raymond James upped their price objective on Hologic from $85.00 to $88.00 and gave the stock an "outperform" rating in a report on Friday, February 2nd. UBS Group upped their price objective on Hologic from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, February 2nd. Finally, Citigroup raised Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd.

Insider Buying and Selling at Hologic

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares of the company's stock, valued at approximately $7,793,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Scott T. Garrett sold 16,441 shares of the firm's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company's stock, valued at $3,670,130.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the firm's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The disclosure for this sale can be found here. Insiders have sold 32,846 shares of company stock valued at $2,473,443 in the last quarter. 1.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Hologic

A number of institutional investors have recently added to or reduced their stakes in HOLX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Hologic by 5.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider's stock valued at $2,569,000 after buying an additional 1,631 shares during the last quarter. LSV Asset Management raised its stake in Hologic by 307.5% in the first quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider's stock valued at $2,911,000 after buying an additional 28,600 shares during the last quarter. Raymond James Trust N.A. raised its stake in Hologic by 7.4% in the first quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider's stock valued at $528,000 after buying an additional 476 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Hologic by 4.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider's stock valued at $177,098,000 after buying an additional 106,315 shares during the last quarter. Finally, Aviva PLC raised its stake in Hologic by 0.7% in the first quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider's stock valued at $5,803,000 after buying an additional 513 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

NASDAQ HOLX traded down $2.43 during trading hours on Tuesday, reaching $75.11. The company's stock had a trading volume of 1,764,609 shares, compared to its average volume of 1,815,527. The firm's 50-day moving average price is $75.66 and its 200-day moving average price is $72.46. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. Hologic has a 1 year low of $64.02 and a 1 year high of $87.88. The company has a market capitalization of $17.63 billion, a price-to-earnings ratio of 35.60, a PEG ratio of 2.62 and a beta of 1.00.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $989.32 million. During the same period in the previous year, the firm earned $1.07 EPS. The firm's revenue was down 5.7% compared to the same quarter last year. On average, equities research analysts predict that Hologic will post 4.02 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.